Auxilium seeks license for Dupuytren’s drug

Auxilium Pharmaceuticals said yesterday that it filed a biologic license application with the U.S. Food and Drug Administration for Xiaflex, a treatment for Dupuytren's contracture, a disease that causes collagen to build up in hands and impairs patients' ability to straighten their fingers.